Indaptus Therapeutics, Inc. entered into a stock purchase agreement on September 8, 2026, to sell 20,338,974 shares of its common stock in a private placement, expecting to raise gross proceeds of approximately $24.0 million. The company plans to use the net proceeds for working capital, research and development, and other general corporate purposes.
Key Details
- Agreement: The company entered into a Stock Purchase Agreement for a private placement on September 8, 2026.
- Transaction Terms: The agreement covers the sale of 20,338,974 shares of common stock, generating gross proceeds of approximately $24.0 million before expenses.
- Use of Proceeds: Funds are allocated for working capital and R&D, which may include preclinical evaluation of a neurotechnology device for certain sleep-related conditions.